# Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania

> **NCT03640403** · PHASE3 · COMPLETED · sponsor: **National Institute for Medical Research, Tanzania** · enrollment: 1555 (actual)

## Conditions studied

- Malaria,Falciparum
- Anemia

## Interventions

- **DRUG:** Dihydroartemisinin-piperaquine
- **DRUG:** Artesunate-amodiaquine

## Key facts

- **NCT ID:** NCT03640403
- **Lead sponsor:** National Institute for Medical Research, Tanzania
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 1555 (ACTUAL)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03640403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03640403, "Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03640403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*